Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pneumococcal polysaccharide conjugate vaccine (10-valent, adsorbed)
- Development stage
- Phase 3
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Synflorix is a 10-valent pneumococcal conjugate vaccine (PHiD-CV) developed by GSK for the prevention of invasive pneumococcal disease (IPD), pneumonia, and acute otitis media (AOM) caused by *Streptococcus pneumoniae* in infants and children. The vaccine contains capsular polysaccharides from 10 pneumococcal serotypes (1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F). A unique feature of this vaccine is the use of a protein derived from non-typeable *Haemophilus influenzae* (NTHi), known as Protein D, as the carrier protein for eight of the ten serotypes, which may provide additional protection against NTHi-related otitis media. The remaining two serotypes are conjugated to tetanus toxoid and diphtheria toxoid. It is formulated with an aluminum phosphate adjuvant.
- Brand names
- Synflorix
- Other names
- 10-valent Streptococcus pneumoniae conjugate vaccine10-valent pneumococcal conjugate vaccine10PCV
02
Targets
PD (Protein D)TT (Tetanus toxoid)SpCPS1 (Streptococcus pneumoniae capsular polysaccharide serotype 1)CPS14 (Streptococcus pneumoniae capsular polysaccharide serotype 14)CPS 18C (Streptococcus pneumoniae capsular polysaccharide serotype 18C)CPS19F (Streptococcus pneumoniae capsular polysaccharide serotype 19F)CPS23F (Streptococcus pneumoniae capsular polysaccharide serotype 23F)CPS4 (Streptococcus pneumoniae capsular polysaccharide serotype 4)PPS5 (Streptococcus pneumoniae capsular polysaccharide serotype 5)6B CPS (Streptococcus pneumoniae serotype 6B capsular polysaccharide)7F CPS (Streptococcus pneumoniae serotype 7F capsular polysaccharide)Streptococcus pneumoniae capsular polysaccharide serotype 9V (PnPS 9V)
Beyond the preview
Go deeper on pneumococcal polysaccharide conjugate vaccine (10-valent, adsorbed).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pneumococcal polysaccharide conjugate vaccine (10-valent, adsorbed).